CTIS2023-508281-15-00招募中1 期
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors - M19-345
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 290
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •For Dose Escalation only: Subjects with an advanced solid tumor who are considered refractory to or intolerant of all existing therapy(ies) known to provide a clinical benefit for their condition. Additionally, subjects who have been offered standard therapies and refused, or who are considered ineligible for standard therapies, may be eligible for this study on a case-by-case basis, after discussion with and agreement from the sponsor., Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1., For Dose Expansion only: Subjects must have measurable disease per RECIST1.1, For Dose Expansion only: All subjects with MSS-CRC, HCC, or pancreatic adenocarcinoma must not have had prior treatment with a PD-1/PDL-1 antagonist in any line of therapy, Subject has adequate bone marrow, renal, hepatic, and coagulation function., For Dose Escalation only: Subjects with pancreatic adenocarcinoma, urothelial cancer, Hepatocellular carcinoma (HCC), or Head and neck squamous cell carcinoma (HNSCC) who are being considered for the dose escalation cohorts must also meet the histology specific eligibility criteria described below for dose expansion., For Dose Expansion only subjects must meet criteria specific to the type of cancer: Pancreatic adenocarcinoma and have disease progression during or after 1 systemic therapy (including gemcitabine monotherapy or in combination with other agents, FOLFIRINOX [or another regimen including both 5-fluorouracil and oxaliplatin], capecitabine monotherapy or in combination with other agents) administered in the adjuvant, locally advanced, or metastatic setting. Progression on more than 1 prior systemic therapy is not allowed in this cohort. If the therapy was used in an adjuvant setting, disease progression must have occurred within 6 months of completing adjuvant therapy., For Dose Expansion only subjects must meet criteria specific to the type of cancer: Urothelial cancer of the bladder and urinary tract and must have progressed following treatment with a platinum-based regimen (administered in any line of therapy) and a programmed death 1/programmed death ligand 1 (PD1/PDL1) antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or anti-PDL1 therapy)., For Dose Expansion only subjects must meet criteria specific to the type of cancer: HCC and must have disease progression during or after 1 prior line of systemic therapy. Progression on more than 1 prior systemic therapy is not allowed in this cohort., For Dose Expansion only subjects must meet criteria specific to the type of cancer: HNSCC (arising from the oral cavity, oropharynx, hypopharynx, or larynx) and must have progressed following treatment with platinum-based regimen (administered in any line of therapy) and a PD1/PDL1 antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or antiPDL1 therapy)., For Dose Expansion only subjects must meet criteria specific to the type of cancer: MSS-CRC subjects with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma (as determined by PCR/NGS or IHC, respectively) who have received prior fluorouracil-based combination chemotherapy regimens including oxaliplatin and irinotecan (with or with
排除标准
- •Has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 5 half-lives or 28 days (whichever is shorter), prior to the first dose of the study drug., Subject has unresolved AEs > Grade 1 from prior anticancer therapy except for alopecia., Has a history of primary immunodeficiency, bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis., Has a known uncontrolled metastases to the central nervous system (with certain exceptions)., Current or prior use of immunosuppressive medication within 14 days prior to the first dose of the study drug.
研究者
相似试验
终止
1 期
A Phase 1 First in Human, Multicenter, Open-Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and RP2D of ABBV-184 in Subjects with Previously Treated Cancers [M19-747]JPRN-jRCT2080225199AbbVie G.K24
招募中
1 期
A study of ISB 2001 in Relapsed/Refractory Multiple MyelomaCTRI/2024/04/065728Ichnos Sciences SA
招募中
1 期
Phase I Dose Finding Study in Patients with HER2-Positive Advanced Solid TumorsHER2-Positive Advanced Solid TumorsCancer - Any cancerACTRN12620000592943Conjugate Light (Australia) Pty Ltd13
撤回
1 期
A First-In-Human, Dose Escalation and Expansion Study of GQ1007 Alone and in Combination with Envafolimab in Subjects with HER2-expressing Advanced Solid TumorsSolid TumorsCancer - Any cancerACTRN12622000513718GeneQuantum Healthcare (Suzhou) Co., Ltd.200
终止
1 期
A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumorseoplastic Disorder - Solid TumorsNeoplastic Disorder - Solid TumorsCancer - Any cancerACTRN12621001342808ChemoCentryx, Inc21